Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Principal Securities Inc.

Principal Securities Inc. increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 25.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 367 shares of the company’s stock after purchasing an additional 75 shares during the quarter. Principal Securities Inc.’s holdings in Medpace were worth $122,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of MEDP. Pallas Capital Advisors LLC raised its holdings in shares of Medpace by 179.7% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after purchasing an additional 2,101 shares in the last quarter. Baillie Gifford & Co. increased its holdings in Medpace by 175.6% in the third quarter. Baillie Gifford & Co. now owns 14,876 shares of the company’s stock valued at $4,966,000 after buying an additional 9,478 shares during the last quarter. Barclays PLC increased its holdings in Medpace by 71.9% in the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after buying an additional 8,275 shares during the last quarter. CWA Asset Management Group LLC acquired a new stake in Medpace in the third quarter valued at $1,306,000. Finally, Oppenheimer Asset Management Inc. lifted its holdings in Medpace by 6.3% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock worth $15,179,000 after buying an additional 2,675 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Medpace stock opened at $340.92 on Wednesday. The stock has a 50-day simple moving average of $343.02 and a 200-day simple moving average of $346.56. The company has a market capitalization of $10.39 billion, a P/E ratio of 26.99, a PEG ratio of 3.81 and a beta of 1.36. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird increased their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.